Editas Medicine
$34.549876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$34.54
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$6.31 (-15.40%) Today
-$0.13 (-0.37%) As of 12:00 AM UTC after-hours
Why Robinhood?
You can buy or sell EDIT and other stocks, options, and ETFs commission-free!
About EDIT
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9).
CEO
James C. Mullen
Employees
235
Headquarters
Cambridge, Massachusetts
Founded
2013
Market Cap
2.22B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.40M
High Today
$39.22
Low Today
$33.58
Open Price
$38.15
Volume
6.79M
52 Week High
$99.95
52 Week Low
$21.41
EDIT News
BenzingaApr 13
CRISPR Therapies Pipeline Insights 2021: Analysis of Key Companies, Emerging Therapies, Recent Happenings and Futuristic Trends
Los Angeles, USA, April 12, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapies Pipeline Insights 2021: Analysis of Key Companies, Emerging Therapies, Recent Happenings a
Analyst Ratings
38%
of 13 ratings
Buy
38%
Hold
38%
Sell
23%
EDIT Earnings
-$1.00
-$0.63
-$0.25
$0.12
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 6, Pre-Market